{
    "nctId": "NCT03137368",
    "briefTitle": "A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations \uff08STEP\uff09",
    "officialTitle": "A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations \uff08STEP\uff09",
    "overallStatus": "UNKNOWN",
    "conditions": "CYP2D6 Polymorphism",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Disease free survival (DFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Providing informed consent forms voluntarily before screening evaluation;\n* For Chinese premenopausal women, her estradiol level must be within the premenopausal level, or the patient meet the following 4 criteria in the prior 6 months: No chemotherapy, Regular menstruation, No use of hormonal, contraceptives, No use of hormone for treatment or for temporary amenorrhea caused by chemotherapy, the estradiol level tested within 8 months after the last dose of chemotherapeutics is within the premenopausal level;\n* Patients with invasive breast cancer which has been confirmed by histological examination;\n* Complete removal of tumor by surgery without local residual;\n* Neoadjuvant chemotherapy before surgery is permitted if the surgery for primary breast cancer is performed within 12 weeks without any further adjuvant chemotherapy, or adjuvant chemotherapy is completed within 8 months;\n* Estrogen receptor (ER) and/or progesterone receptor (PR) positive: If the patient has more than one breast tumor lesions, each tumor lesion should be ER and/or PR positive.\n* Her-2 negative;\n* Genotyping test performed by the central laboratory designated by sponsor with the results confirmed as CYP2D6\\*10T/T gene mutation.\n* Women of childbearing age with negative serum pregnancy test result, and agreeing to adopt highly efficient non-hormonal contraception measure throughout the study;\n* Subject without major organ dysfunction, and with normal heart, liver, kidney, lung and other major organ function.\n\nExclusion Criteria:\n\n* Inflammatory breast cancer;\n* Breast cancer patients with supraclavicular lymph nodes metastasis;\n* Patients with enlarged internal mammary lymph nodes (except for patients with negative pathologic findings);\n* Ovariectomy which is not specified in the study;\n* Patients with ovary protection during the chemotherapy;\n* Concomitant use of other aromatase inhibitors (not Exemestane);\n* Received major surgery which was unrelated to breast cancer within four weeks before randomization, or the patients had not yet fully recovered from such surgery;\n* Pregnant or lactating women;\n* Known active hepatitis B or hepatitis C or HIV;\n* Having difficulty in swallowing oral preparations and gastrointestinal dysfunction;\n* Recently had severe and uncontrolled systemic diseases (e.g.: cardiovascular disease, lung disease, or metabolic disease, venous thrombosis with clinical significance);\n* Currently or previously suffering from other malignant tumors (except for skin basal cell carcinoma or squamous cell carcinoma, carcinoma in situ of cervix which had been fully treated), unless a radical treatment had been done with the evidence of no-recurrence or metastasis in nearly five years;\n* Allergic to any study drug or any ingredients of drug;\n* Patient with poor compliance or other conditions which makes the patient unsuitable to participate in this study judged by the investigator.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}